May 12, 2025
TOPLINE: Early rituximab monotherapy led to a substantial delay in the need for new treatment in patients with advanced stage, asymptomatic, low tumour burden follicular lymphoma. […]
May 12, 2025
In the spring of 2024, the US Food and Drug Administration (FDA) approved fidanacogene elaparvovec (Beqvez), only the second gene therapy product for hemophilia B. Just […]
May 12, 2025
TOPLINE: In the multicenter PLATO-ACT4 trial, patients with early-stage anal cancer who received reduced-dose chemoradiotherapy had higher complete clinical response rates at 6 months and experienced […]
May 12, 2025
A study has revealed that regular exercise can improve erectile dysfunction after treatment for prostate cancer, highlighting the importance of physical activity in sexual rehabilitation, particularly […]
May 12, 2025
In response to the alarming rise in digestive cancers among young adults, doctors, researchers, patients, and European policymakers are urging Europe to rethink its strategies for […]
May 9, 2025
TOPLINE: Pain, nausea, and vomiting were the most frequently documented symptoms preceding unplanned acute care visits in patients with cancer, new research showed. Women, individuals from […]
May 9, 2025
In the 11 years since it was approved for the treatment of melanoma, pembrolizumab (Keytruda) has become the go-to for adjuvant or neoadjuvant therapy for advanced […]
May 9, 2025
TOPLINE: Short-interval CT demonstrated spontaneous resolution of consolidation in more than 50% of lung cancer screening participants, while persistent consolidation showed a 29.8% risk for malignancy. […]
May 8, 2025
The US Food and Drug Administration (FDA) has granted accelerated approval of combination avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for the treatment of certain […]